Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine

Cancer Research

Volumn 59, Issue 20, 1999, Pages 5264-5269

  Pan, Zhen Kun ^b   Weiskirch, Larry M ^b   Paterson, Yvonne ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LISTERIA MONOCYTOGENES; LUNG METASTASIS; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; BACTERIAL VACCINES; CYTOKINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LISTERIA MONOCYTOGENES; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RNA, MESSENGER; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0032723880     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Weiskirch, L. M., and Paterson, Y. Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease. Immunol. Rev., 158: 159-169, 1997.
2. Pan, Z-K., Ikonomidis, G., Lazenby, A., Pardoll, D., and Paterson, Y. A recombinant Listeria monocytogenes vaccine expressing a model tumor antigen protects mice against lethal tumor challenge and causes regression of established tumors. Nat. Med., 1: 471-477, 1995.
3. Pan, Z-K., Ikonomidis, G., Pardoll, D., and Paterson, Y. Regression of established cancer mediated by the oral delivery of a recombinant Listeria monocytogenes vaccine expressing a model tumor antigen. Cancer Res., 55: 4776-4779, 1995.
4. Fidler, I. J. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res., 35: 218-234, 1975.
5. 2 terminus of the nucleoprotein gene does not affect generation of cytotoxic T lymphocyte epitopes. J. Immunol., 147: 2697-2705, 1991.
6. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone-marrow derived cells in presenting MHC class 1 restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
7. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 20: 3539-3543, 1993.
8. Ikonomidis, G., Paterson, Y., Kos, F. J., and Portnoy, D. A. Delivery of a viral antigen to the class I processing and presentation pathway of Listeria monocytogenes. J. Exp. Med., 180: 2209-2218, 1994.
9. Frankel, F. R., Hegde, S., Lieberman, J., and Paterson, Y. Induction of a cell-mediated immune response to HIV gag using Listeria monocytogenes as a live vaccine vector. J. Immunol., 155: 4766-4774, 1995.
10. North, R. J., Berche, P., and Newborg, M. F. Immunologic consequences of antibiotic-induced abridgement of bacterial infection: effect on generation and loss of protective T cells and level of immunologic memory. J. Immunol., 127: 342-346, 1981.
11. Mule, J. J., Yang, J. C., Afreniere, R. L., Shu, S. Y., and Rosenberg, S. A. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J. Immunol., 139: 285-294, 1987.
12. Slingluff, C. L., Hunt, D. F., and Engelhard, V. H. Direct analysis of tumor-associated peptide antigens. Curr. Opin. Immunol., 6: 733-740, 1994.
13. Boon, T., and Old, L. J. Cancer tumor antigens. Curr. Opin. Immunol., 9: 681-683. 1997.
14. Falo, L. D., Kovacsovics-Bankowski, M., Thompson, K., and Rock, K. L. Targeting antigen into the phagocytic pathway in vivo induces protective tumor immunity. Nat. Med., 1: 649-653, 1995.
15. Restifo, N. P., and Rosenberg, S. A. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr. Opin. Oncol., 11: 50-57, 1999.
16. Przepiorka, D., and Srivastava, P. K. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol. Med. Today, 4: 478-484, 1998.
17. Ikonomidis, G., and Paterson, Y. Recombinant Listeria monocytogenes cancer vaccines. Curr. Opin. Immunol., 8: 564-669, 1996.
18. + T cells in the anti-tumor immune response. J. Exp. Med., 188: 2357-2368, 1999.
19. Brunda, M. J., Wright, R. B., Luistro, L., Harbison, M. L., Anderson, T. D., and McIntyre, K. W. Enhanced antitumor efficacy in mice by combination treatment with interleukin-1 α and interferon-α. J. Immunother. Emphas. Tumor Immunol., 15: 233-241, 1994.
20. Giacomini, P., Fraioli, R., Nistico, P., Tecce, R., Nicotra, M. R., Di Filippo, F., Fisher, P. B., and Natali, P. G. Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. Int. J. Cancer, 46: 539-545, 1990.
21. Seliger, B., Hohne, A., Knuth, A., Bernhard, H., Meyer, T., Tampe, R., Momburg, F., and Huber, C. Analysis of the major histocompatibilily complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res., 56: 1756-1760, 1996.
22. Watanabe, M., McCormick, K. L., Volker, K., Ortaldo, J. R., Wigginton, J. M., Brunda, M. J., Wiltrout, R. H., and Fogler, W. E. Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am. J. Pathol., 150: 1869-1880, 1997.
23. Villasor, R. P. The clinical use of BCG vaccine in stimulating host resistance to cancer. J. Philipp. Med. Assoc., 41: 619-632, 1965.
24. Jackson, A. M., Alexandroff, A. B., Kelly, R. W., Skibinska, A., Esuvaranathan, K., Prescott, S., Chisholm, G. D., and James, K. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guérin (BCG) immunotherapy. Clin. Exp. Immunol., 99: 369-375, 1995.
25. Low, K. B., Ittensohn, M., Le, T., Platt, J., Sodi, S., Amoss, M., Ash, O., Carmichael, E., Chakraborty, A., Fischer, J., Lin, S. L., Luo, X., Miller, S. I., Zheng, L., King, I., Pawelek, J. M., and Bermudes, D. Lipid A mutant Salmonella with suppressed virulence and TNF-α induction retain tumor-targeting in vivo. Nat. Biotechnol., 17: 37-41, 1999.